A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-12-31

Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.

• Phase: PHASE3

Details

• Lead Sponsor: RemeGen Co., Ltd.
• Treatments: Capecitabine; disitamab vedotin; Oxaliplatin; pembrolizumab; tislelizumab; Trastuzumab